Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 11Head and Neck Neoplasms 4Adenocarcinoma 2Squamous Cell Carcinoma of Head and Neck 1Carcinoma, Squamous Cell 1Breast Neoplasms 1

Interventions

Cisplatin 8Radiotherapy 5Paclitaxel 5Docetaxel 5Cetuximab 4Carboplatin 4pembrolizumab 3figitumumab 2cemiplimab 2advexin 2Radiation 2Methotrexate 2Fluorouracil 2Drug Therapy 2Bleomycin 2vandetanib 1talimogene laherparepvec 1sintilimab 1nedaplatin 1nanocis 1methyl 5-aminolevulinate 1ficlatuzumab 1dusquetide 1brigatinib 1avasopasem manganese 1alpha-2'-deoxythioguanosine 1Vinorelbine 1Tretinoin 1Tirapazamine 1Technetium-99 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Squamous Cell × Afatinib × Clear all
NCT01345682 2018-02-15

LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy

Boehringer Ingelheim

Phase 3 Completed
483 enrolled 21 charts
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡